长春高新：公司将按照法律法规要求履行相应的披露义务

Core Viewpoint - Changchun Gaoxin has received clinical approval for treatments targeting specific conditions related to hormone deficiencies and congenital adrenal hyperplasia, indicating a focus on niche medical needs and potential market opportunities [2] Group 1 - The company has been approved for clinical indications to improve conditions caused by hypergonadotropic hypogonadism, 5α-reductase type 2 deficiency, congenital adrenal hyperplasia, and idiopathic causes leading to penile hypoplasia in children [2] - The company commits to fulfilling disclosure obligations as per legal regulations if new situations arise that meet disclosure standards in the future [2]